JP2003111834A - Adsorbent for immunosuppressive protein and column for extracorporeal circulation - Google Patents
Adsorbent for immunosuppressive protein and column for extracorporeal circulationInfo
- Publication number
- JP2003111834A JP2003111834A JP2001307333A JP2001307333A JP2003111834A JP 2003111834 A JP2003111834 A JP 2003111834A JP 2001307333 A JP2001307333 A JP 2001307333A JP 2001307333 A JP2001307333 A JP 2001307333A JP 2003111834 A JP2003111834 A JP 2003111834A
- Authority
- JP
- Japan
- Prior art keywords
- immunosuppressive
- water
- adsorbent according
- adsorbent
- immunosuppressive protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003463 adsorbent Substances 0.000 title claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 21
- 230000001506 immunosuppresive effect Effects 0.000 title claims abstract description 20
- 150000001412 amines Chemical class 0.000 claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 9
- 108010014723 immunosuppressive acidic protein Proteins 0.000 claims abstract description 8
- 239000000835 fiber Substances 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 16
- -1 poly (aromatic vinyl compound Chemical class 0.000 claims description 11
- 229920002492 poly(sulfone) Polymers 0.000 claims description 11
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- QMHNQZGXPNCMCO-UHFFFAOYSA-N n,n-dimethylhexan-1-amine Chemical compound CCCCCCN(C)C QMHNQZGXPNCMCO-UHFFFAOYSA-N 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004697 Polyetherimide Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000274 adsorptive effect Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229920001601 polyetherimide Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- TXNSZCSYBXHETP-UHFFFAOYSA-N 2-chloro-n-(hydroxymethyl)acetamide Chemical compound OCNC(=O)CCl TXNSZCSYBXHETP-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005179 haloacetyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- YWFWDNVOPHGWMX-UHFFFAOYSA-N n,n-dimethyldodecan-1-amine Chemical compound CCCCCCCCCCCCN(C)C YWFWDNVOPHGWMX-UHFFFAOYSA-N 0.000 description 2
- UQKAOOAFEFCDGT-UHFFFAOYSA-N n,n-dimethyloctan-1-amine Chemical compound CCCCCCCCN(C)C UQKAOOAFEFCDGT-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- ZNPJKSCIHJSEQZ-UHFFFAOYSA-N 4-methoxy-n,n-dimethylbutan-1-amine Chemical compound COCCCCN(C)C ZNPJKSCIHJSEQZ-UHFFFAOYSA-N 0.000 description 1
- QCXNXRUTKSIZND-UHFFFAOYSA-N 6-(dimethylamino)hexan-1-ol Chemical compound CN(C)CCCCCCO QCXNXRUTKSIZND-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical group N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920000265 Polyparaphenylene Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 101000716136 Rattus norvegicus Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000616771 Rattus norvegicus Magnesium transporter protein 1 Proteins 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940047583 cetamide Drugs 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- IBBQVGDGTMTZRA-UHFFFAOYSA-N sodium;2-sulfobenzene-1,3-dicarboxylic acid Chemical compound [Na].OC(=O)C1=CC=CC(C(O)=O)=C1S(O)(=O)=O IBBQVGDGTMTZRA-UHFFFAOYSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、血液中に過剰に存
在すれば免疫の大幅な低下を招き、癌の形成が促進され
るTGFβや免疫抑制酸性蛋白などの免疫抑制性蛋白質
を除去するための吸着材および体外循環カラムに関す
る。TECHNICAL FIELD [0001] The present invention is for removing immunosuppressive proteins such as TGFβ and immunosuppressive acidic proteins which, if excessively present in blood, lead to a significant decrease in immunity and promote the formation of cancer. Adsorbent and extracorporeal circulation column.
【0002】[0002]
【従来の技術】医学の発達した今日でも、依然として日
本人の主な死亡原因の一つが癌である。その原因は患者
には手術で取りきれない癌細胞が存在するためであり、
その除去のため抗癌剤治療や放射線治療が行われてき
た。しかし、これらは正常細胞をも傷害するため患者の
生命を維持しつつ癌細胞を完全に除去することができな
い。一方、最近、患者の免疫力を高めて、患者自身の白
血球で癌を排除しようとする細胞療法が盛んに試みられ
る様になった。最も有望なものとして、患者の樹状細胞
を体外で癌抗原刺激した後、患者に戻し、癌特異的キラ
ー細胞(CTL)を誘導して治療しようとする樹状細胞
輸注療法がある。しかし、健康な動物の血液からはCT
Lを誘導できても癌末期の担癌動物からは誘導できない
ことが多い。また、動物実験では好成績を得ても臨床で
は目に見えた効果が出ないことが殆どである。この理由
として患者の血中には免疫を抑制する物質が存在するた
めと考えられる。その免疫抑制物質の代表的なものがト
ランスフォーミング・グロウス・ファクター・ベータ
(TGFβ)や免疫抑制酸性蛋白である。この物質がC
TLの誘導や機能発現を阻害していると考えられる。T
GFβは、健康な人の血液中にも存在する蛋白質で免疫
作用を調整する重要な物質であるが、癌の進行に伴って
異常に増え、癌細胞の増殖を助けていると考えられる。
TGFβは単独では分子量25000程度の蛋白質であ
るが、血中では他の蛋白質と結合して10万前後の分子
量で存在するため、従来の吸着材では吸着除去が困難な
物質である。従って、癌患者の血液中から異常に増えた
TGFβを効率よく除去できる吸着材は知られていな
い。また、免疫抑制酸性蛋白は分子量5万程度の蛋白質
で、癌の悪性度のマーカーとして臨床で利用されている
が、免疫を抑制すると言われている。活性炭カラムでの
除去も試みられたが、吸着能力が不十分だったためか治
療効果が明確でなかった。また、活性炭は粉が出やすい
ので、直接、血液と接触する用途には向かない。これら
免疫抑制物質の除去には、理論上、血漿交換も有効であ
るが、感染の危険が避けがたい本質的な欠点がある。2. Description of the Related Art Even with the advance of medical science, cancer remains one of the leading causes of death in the Japanese people. The reason is that the patient has cancer cells that cannot be removed by surgery,
Anticancer drug treatment and radiation treatment have been performed to remove them. However, since these also damage normal cells, the cancer cells cannot be completely removed while maintaining the life of the patient. On the other hand, recently, cell therapy has been actively attempted to enhance the immunity of the patient and eliminate the cancer with the patient's own white blood cells. The most promising one is dendritic cell infusion therapy in which a patient's dendritic cells are stimulated with cancer antigen in vitro and then returned to the patient to induce and treat cancer-specific killer cells (CTL). However, CT from the blood of healthy animals
Even if L can be induced, it often cannot be induced from a tumor-bearing animal at the end stage of cancer. Moreover, even if good results are obtained in animal experiments, in most cases clinically no observable effects are obtained. It is considered that this is because there are substances that suppress immunity in the blood of patients. Typical examples of the immunosuppressive substances are transforming growth factor beta (TGFβ) and immunosuppressive acidic protein. This substance is C
It is considered that TL induction and functional expression are inhibited. T
GFβ is a protein that is also present in the blood of healthy people and is an important substance that regulates the immune action, but it is thought to increase abnormally with the progression of cancer and help the growth of cancer cells.
TGFβ is a protein having a molecular weight of about 25,000 by itself, but since it is bound to other proteins in blood and has a molecular weight of about 100,000, it is a substance difficult to adsorb and remove with a conventional adsorbent. Therefore, an adsorbent that can efficiently remove the abnormally increased TGFβ from the blood of cancer patients is not known. Further, the immunosuppressive acidic protein is a protein having a molecular weight of about 50,000 and is clinically used as a marker of malignancy of cancer, but is said to suppress immunity. An attempt was made to remove it using an activated carbon column, but the therapeutic effect was not clear, probably because the adsorption capacity was insufficient. In addition, activated carbon is not suitable for applications where it comes into direct contact with blood because activated carbon easily produces powder. In theory, plasma exchange is also effective in removing these immunosuppressive substances, but there is an essential drawback that the risk of infection is unavoidable.
【0003】[0003]
【発明が解決しようとする課題】本発明は、かかる従来
技術の問題点に鑑み、一般的に普及可能であり、体液中
から、直接、TGFβや免疫抑制酸性蛋白などの免疫抑
制物質を高い効率で選択的に吸着し、かつ、安全に体外
循環できる免疫抑制性蛋白質吸着材を提供し、ひいては
癌の治療に役立てることを目的とする。In view of the above problems of the prior art, the present invention is widely applicable, and it is possible to directly obtain an immunosuppressive substance such as TGFβ or immunosuppressive acidic protein with high efficiency from a body fluid. It is an object of the present invention to provide an immunosuppressive protein adsorbent that can be selectively adsorbed by and can be safely extracorporeally circulated, and eventually be useful for treating cancer.
【0004】[0004]
【課題を解決するための手段】すなわち本発明は、比表
面積が1グラム当たり0.1平方メートル以上であり、
不溶性担体に親水性アミン残基を結合してなる免疫抑制
性蛋白質の吸着材である。That is, the present invention has a specific surface area of 0.1 square meter or more per gram,
An adsorbent for an immunosuppressive protein, which comprises a hydrophilic amine residue bound to an insoluble carrier.
【0005】また本発明は、上記の吸着材を充填した体
外循環カラムである。Further, the present invention is an extracorporeal circulation column packed with the above-mentioned adsorbent.
【0006】[0006]
【発明の実施の形態】続いて、本発明についてさらに詳
細に説明する。BEST MODE FOR CARRYING OUT THE INVENTION Next, the present invention will be described in more detail.
【0007】本発明で用いる水不溶性担体としては、水
に不溶で、親水性アミンを固定化できるものであれば良
く、特に制限はない。水不溶性担体の具体例としてはポ
リスチレンで代表されるポリ(芳香族ビニル化合物)、
ポリ(p−フェニレンエーテルスルホン)や−{(p−
C6 H4 )−C(CH3)2−(p−C6 H4 )−O−
(p−C6 H4 )−SO2 −(p−C6 H 4 )−O−}
n−(以下ユーデルポリスルホンと略記する)などで代
表されるポリスルホン系重合体、ポリエーテルイミド、
ポリイミド、ポリアミド、ポリエーテル、ポリフェニレ
ンサルファイドなどで、かつ、親水性アミンを固定化で
きるものがあげられる。親水性アミンを固定化するため
の反応性官能基としては、ハロメチル基、ハロアセチル
基、ハロアセトアミドメチル基、ハロゲン化アルキル基
などの活性ハロゲン基、エポキサイド基、カルボキシル
基、イソシアン酸基、チオイソシアン酸基、酸無水物基
などをあげることができるが、とりわけ、活性ハロゲン
基、中でも、ハロアセチル基は、製造が容易な上に、反
応性が適度に高く、親水性アミンの固定化反応が温和な
条件で遂行できると共に、この際生じる共有結合が化学
的に安定なので好ましい。さらに具体的な例としては、
クロルアセトアミドメチルポリスチレン、クロルアセト
アミドメチル化したユーデル・ポリスルホン、クロルア
セトアミドメチル化したポリエーテルイミドなどがあげ
られる。さらに、これらのポリマーは有機溶媒に対し可
溶であると、成型しやすい利点がある。The water-insoluble carrier used in the present invention is water.
So long as it is insoluble in and can immobilize hydrophilic amines
There is no particular limitation. Specific examples of the water-insoluble carrier include po
Poly (aromatic vinyl compound) represented by styrene,
Poly (p-phenylene ether sulfone) or-{(p-
C6HFour) -C (CH3)2-(P-C6HFour) -O-
(P-C6HFour) -SO2-(P-C6H Four) -O-}
n-(Uder polysulfone)
Represented polysulfone polymer, polyetherimide,
Polyimide, polyamide, polyether, polyphenylene
And immobilize hydrophilic amine
I can give you what I can. To immobilize hydrophilic amines
The reactive functional groups of are halomethyl group, haloacetyl group
Group, haloacetamidomethyl group, halogenated alkyl group
Active halogen groups such as, epoxide groups, carboxyl
Group, isocyanic acid group, thioisocyanic acid group, acid anhydride group
And the like, but especially active halogen
Group, especially haloacetyl group, is easy to manufacture and
The reactivity is moderately high, and the immobilization reaction of hydrophilic amine is mild.
It can be carried out under conditions, and the covalent bond generated at this time is chemically
Is stable, which is preferable. As a more specific example,
Chloracetamidomethyl polystyrene, chloracetate
Amdelmethylated Udel Polysulfone, Chlorua
Cetamide methylated polyether imide etc.
To be Furthermore, these polymers are compatible with organic solvents.
Melting has the advantage of being easy to mold.
【0008】本発明で言う親水性アミン残基とは、単独
では水に溶解もしくは水を溶解するアミンがポリマーに
化学的に結合した状態のものを意味する。さらに、親水
性アミン残基の親水性アミンとしては、炭素数で言う
と、窒素原子1個当たり炭素数18以下であるものがこ
れに相当する。The term "hydrophilic amine residue" as used in the present invention means a state in which a water-soluble or water-soluble amine is chemically bonded to a polymer. Further, the hydrophilic amine of the hydrophilic amine residue corresponds to one having a carbon number of 18 or less per nitrogen atom in terms of carbon number.
【0009】さらに、親水性アミンの中でも、窒素原子
1個当たり炭素数3以上18以下、とりわけ、4以上1
4以下のアルキル基を持つ第3級アミンから得られる第
4アンモニウム基を結合したものが優れている。そのよ
うな第3級アミンの具体例としては、トリメチルアミ
ン、トリエチルアミン、N、N−ジメチルヘキシルアミ
ン、N、N−ジメチルオクチルアミン、N,N−ジメチ
ルラウリルアミン、N−メチル−N−エチル−ヘキシル
アミンなどがあげられる。さらに、親水性アミンを構成
するアルキル基が親水性基である水酸基やエーテル基を
含むもの、例えば、N,N−ジメチル−6−ヒドロキシ
ヘキシルアミンやN,N−ジメチル−4−メトキシブチ
ルアミン等も親水性アミンとして好ましく用いうる。Further, among the hydrophilic amines, the number of carbon atoms per nitrogen atom is 3 or more and 18 or less, and particularly 4 or more and 1 or less.
Those having a quaternary ammonium group obtained from a tertiary amine having an alkyl group of 4 or less are excellent. Specific examples of such a tertiary amine include trimethylamine, triethylamine, N, N-dimethylhexylamine, N, N-dimethyloctylamine, N, N-dimethyllaurylamine, N-methyl-N-ethyl-hexyl. Examples include amines. Further, those in which the alkyl group constituting the hydrophilic amine contains a hydroxyl group or an ether group, which are hydrophilic groups, such as N, N-dimethyl-6-hydroxyhexylamine and N, N-dimethyl-4-methoxybutylamine It can be preferably used as a hydrophilic amine.
【0010】本発明における親水性アミン残基の結合の
密度は、水不溶性重合体の化学構造および用途により異
なるが、少なすぎるとその機能が発現しない傾向にあ
り、一方、多すぎると、固定化後の重合体の物理的強度
が悪くなり、吸着材としての機能も下がる傾向にあるの
で、該密度は水不溶性重合体の繰り返し単位あたり0.
01〜2.0モル、より好ましくは0.1〜1.0モル
が良い。The bond density of the hydrophilic amine residue in the present invention varies depending on the chemical structure and use of the water-insoluble polymer, but if it is too small, its function tends not to be exhibited, while if it is too large, it is immobilized. Since the physical strength of the polymer afterwards tends to be poor and the function as an adsorbent tends to be lowered, the density is 0. 0 per repeating unit of the water-insoluble polymer.
The amount is preferably 01 to 2.0 mol, more preferably 0.1 to 1.0 mol.
【0011】本発明の吸着材の表面積は吸着材1グラム
当たり0.1平方メートル以上であることが重要であ
り、より好ましくは、1平方メートル以上である。ただ
し無限に大きくはできないので、実際上、限界があり、
100平方メートル以下が好ましい。この表面積は窒素
ガス吸着法(BET法)で求めることができる。It is important that the surface area of the adsorbent of the present invention is 0.1 m 2 or more per gram of the adsorbent, and more preferably 1 m 2 or more. However, since it cannot be made infinitely large, there is a practical limit,
100 square meters or less is preferable. This surface area can be determined by the nitrogen gas adsorption method (BET method).
【0012】本発明の吸着材は、親水性アミン残基を結
合した水不溶性重合体を膜、繊維、粒状物またはこれら
の組み立て品に成型するか、あるいは親水性アミン残基
を結合した水不溶性重合体を、膜、繊維、粒状物のいず
れかの基材に被覆せしめるか、あるいは水不溶性重合体
の膜、繊維等の成型品に親水性アミンを結合させるか等
により得ることができる。The adsorbent of the present invention is formed by molding a water-insoluble polymer having a hydrophilic amine residue bonded into a film, a fiber, a granular material or an assembly thereof, or a water-insoluble polymer having a hydrophilic amine residue bonded. It can be obtained by coating the polymer with a base material of a film, a fiber, or a granular material, or by bonding a hydrophilic amine to a molded product such as a water-insoluble polymer film or a fiber.
【0013】親水性アミン残基を結合した水不溶性担体
の成型品の製造には、水不溶性重合体の成型品に親水性
アミンの溶液を接触させる不均一系反応の方法と水不溶
性重合体の溶液と親水性アミンの溶液を混合して反応さ
せた後、成型する均一系反応の方法とがある。不均一系
反応の方法の一例としては、クロルアセトアミドメチル
化ポリスルホンの繊維または中空糸などの成型品をジメ
チルヘキシルアミンやポリアルキレンイミン等のイソプ
ロパノール溶液中に浸し、0〜100℃の温度で反応さ
せることにより、容易に達成される。均一系反応による
方法の一例を述べると、クロルアセトアミドメチル化ポ
リスルホンの溶液中に対応したポリアミンを加えて、0
〜100℃の温度で反応させることにより、達成され
る。その量には特に制限はないが、可溶性のポリマーを
得るためにはハロアセトアミドメチル基に対し1倍モル
以上用いるのが望ましい。とりわけ、ポリアミンの場合
は、可溶性の重合体を得るためには親水性アミンを大過
剰用いるのが好ましい。In order to produce a molded product of a water-insoluble carrier having a hydrophilic amine residue bonded thereto, a method of heterogeneous reaction in which a solution of a hydrophilic amine is brought into contact with a molded product of a water-insoluble polymer, There is a homogeneous reaction method in which a solution and a hydrophilic amine solution are mixed and reacted, and then molded. As an example of the heterogeneous reaction method, a molded article such as a chloroacetamidomethylated polysulfone fiber or hollow fiber is dipped in an isopropanol solution such as dimethylhexylamine or polyalkyleneimine and reacted at a temperature of 0 to 100 ° C. This is easily achieved. An example of the homogeneous reaction method is as follows. Add the corresponding polyamine to a solution of chloroacetamidomethylated polysulfone, and add 0
This is achieved by reacting at a temperature of ~ 100 ° C. The amount is not particularly limited, but in order to obtain a soluble polymer, it is desirable to use 1 times or more moles with respect to the haloacetamidomethyl group. In particular, in the case of polyamine, it is preferable to use a large excess of hydrophilic amine in order to obtain a soluble polymer.
【0014】また、反応溶媒としては、水、メタノー
ル、エタノール、イソプロパノール、ジメチルスルホキ
シド、N,N−ジメチルホルムアミド(DMF)などの
極性の高い溶媒の方が反応が速く進む利点がある。不均
一系反応では、親水性アミンが溶ける溶媒であれば良
く、特に制限はない。均一系で反応させる場合には、水
不溶性担体と親水性アミンの両方が溶解する溶媒、具体
的にはテトラヒドロフラン、ジメチルスルホキシド、
N,N−ジメチルホルムアミド、N,N−ジメチルアセ
トアミド、N−メチルピロリドンなどが好ましく用いら
る。また、成型品を表面処理する方法も可能で、そのた
めには水、メタノール、エタノールなどの、ポリスルホ
ンを溶かさずに親水性アミンを溶かす溶媒が好ましく用
いられる。As the reaction solvent, a solvent having a high polarity such as water, methanol, ethanol, isopropanol, dimethylsulfoxide, N, N-dimethylformamide (DMF) has the advantage that the reaction proceeds faster. The heterogeneous reaction is not particularly limited as long as it is a solvent in which the hydrophilic amine can be dissolved. When the reaction is carried out in a homogeneous system, a solvent in which both the water-insoluble carrier and the hydrophilic amine are dissolved, specifically tetrahydrofuran, dimethylsulfoxide,
N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone and the like are preferably used. A method of surface-treating the molded product is also possible, and for that purpose, a solvent such as water, methanol or ethanol that dissolves the hydrophilic amine without dissolving the polysulfone is preferably used.
【0015】本発明の吸着材ポリマーをポリエステル繊
維、ナイロン繊維、ポリフェニレンサルファイド繊維な
どの成型品の表面にコーティングすると、簡単且つ安価
に表面積の大きな高次の成型品が得られる利点がある。
コーティングは、本発明の吸着材を塩化メチレンやテト
ラヒドロフランなどの低沸点溶媒に溶かしたものにナイ
ロンの編み地や織物を浸したのち、溶媒を蒸発すること
により容易に達成できる。また、N,N−ジメチルホル
ムアミドなどの溶媒に溶かしたものを水などのポリマー
の貧溶媒に入れる湿式コーティング法も利用できる。コ
ーティングされる成型品のポリマーはポリアミド、ポリ
ウレタン、ポリイミド、ポリスルホン、ポリ塩化ビニ
ル、ポリエステルなど、本発明吸着材ポリマーとの接着
性の良いものであれば何でも良く、その種類には特に制
限はないが、ナイロン、ポリエーテルイミドなどのアミ
ド系のポリマーが接着性が特に良いので、好ましく用い
られる。When the adsorbent polymer of the present invention is coated on the surface of a molded product such as polyester fiber, nylon fiber, polyphenylene sulfide fiber, there is an advantage that a high-order molded product having a large surface area can be obtained easily and inexpensively.
The coating can be easily accomplished by immersing the nylon knitted fabric or woven fabric in a solution of the adsorbent of the present invention in a low boiling point solvent such as methylene chloride or tetrahydrofuran, and then evaporating the solvent. Further, a wet coating method can also be used in which a substance dissolved in a solvent such as N, N-dimethylformamide is put in a poor solvent for a polymer such as water. The polymer of the molded product to be coated may be any polymer having good adhesiveness to the adsorbent polymer of the present invention, such as polyamide, polyurethane, polyimide, polysulfone, polyvinyl chloride, polyester, etc., but the type thereof is not particularly limited. Amide polymers such as nylon, polyetherimide and the like have particularly good adhesiveness and are preferably used.
【0016】上記の成型や基材への被覆において、成型
品や基材の形態に採用する繊維として、中空糸を用いる
ことも好ましい。この場合、濾過の機能を具備した吸着
材が作れるので、人工透析器として、あるいは、血漿分
離器として使用しながら免疫抑制物質を除去できる利点
がある。In the above-mentioned molding or coating on the base material, it is also preferable to use hollow fibers as the fibers employed in the form of the molded product or the base material. In this case, since an adsorbent having a filtering function can be prepared, there is an advantage that the immunosuppressive substance can be removed while being used as an artificial dialyzer or a plasma separator.
【0017】本発明の吸着材は血液中のTGFβ、免疫
抑制酸性蛋白などの免疫抑制性蛋白質の除去の目的で、
カラムに詰めた状態で、癌等の病気の体外循環治療に用
いられる。本カラム作製は、綿状、筒編み状、フェルト
状の本発明吸着材を、空隙容積が200mL程度以下に
なるようにして、適度の大きさの円筒形のカラムに詰め
ることで達成できる。また、本発明吸着材は輸血用血
液、血清、血漿からの免疫抑制性蛋白質の除去の目的に
も用いることができる。The adsorbent of the present invention is used for the purpose of removing TGFβ, immunosuppressive acidic proteins and other immunosuppressive proteins in blood,
It is used for extracorporeal circulation treatment of diseases such as cancer in a state packed in a column. The present column can be prepared by filling the adsorbent of the present invention in the form of cotton, cylinder knit, or felt into a cylindrical column of appropriate size such that the void volume is about 200 mL or less. The adsorbent of the present invention can also be used for the purpose of removing immunosuppressive proteins from blood for transfusion, serum, and plasma.
【0018】[0018]
【実施例】以下、実験例により本発明をさらに具体的に
説明する。EXAMPLES The present invention will be described in more detail with reference to experimental examples.
【0019】なお、本実施例中の評価方法は、以下に従
った。
1.血液中の成分の分析
TGFβ1濃度はゼンザイム・テクネ社のヒトTGF−
β1免疫分析キットを使用して求めた。また免疫抑制酸
性蛋白の濃度は、三光純薬社製のラットIAPプレート
を使用して求めた。アルブミン濃度はアルブミン分析キ
ットであるアルブミンB−テストワコーで求めた。The evaluation method in this example was as follows. 1. Analysis of components in blood The concentration of TGFβ1 is the human TGF- of Zenzyme Techne.
Determined using the β1 immunoassay kit. The concentration of immunosuppressive acidic protein was determined using a rat IAP plate manufactured by Sanko Junyaku Co., Ltd. The albumin concentration was determined using an albumin analysis kit, Albumin B-Test Wako.
【0020】(水不溶性担体)36島の海島複合繊維で
あって、島が更に芯鞘複合によりなるものを次の成分を
用いて、紡糸速度800m/分、延伸倍率3倍の製糸条
件で得た。
島の芯成分;ポリプロピレン
島の鞘成分;ポリスチレン90%、ポリプロピレン10
%
海成分;5−ナトリウムスルホイソフタル酸を3%共重
合したポリエチレンテレフタレート
複合比率;芯:鞘:海=40:40:20。
この海成分を熱苛性ソーダ水溶液で溶解し、芯鞘型のポ
リプロピレン補強ポリスチレン繊維として、直径4μm
の原糸1を得た。(Water-insoluble carrier) A sea-island composite fiber having 36 islands, wherein the island is further composed of a core-sheath composite, was obtained using the following components under the spinning conditions of a spinning speed of 800 m / min and a draw ratio of 3 times. It was Island core component: Polypropylene Island sheath component: Polystyrene 90%, Polypropylene 10
% Sea component; polyethylene terephthalate composite ratio obtained by copolymerizing 5% sodium sulfoisophthalic acid 3%; core: sheath: sea = 40:40:20. This sea component is dissolved in a hot caustic soda aqueous solution to form a core-sheath type polypropylene reinforced polystyrene fiber having a diameter of 4 μm.
Yarn 1 was obtained.
【0021】また、吐出量や延伸倍率を適宜変更し、同
様にして直径10μmの原糸2、直径50μmの原糸3
を得た。Further, the discharge amount and the draw ratio are appropriately changed, and similarly, a yarn 2 having a diameter of 10 μm and a yarn 3 having a diameter of 50 μm are obtained.
Got
【0022】(中間体)ニトロベンゼン600mLと硫
酸390mLの混合溶液にパラホルムアルデヒド3gを
20℃で溶解した後、0℃に冷却し、75.9gのN−
メチロール−α−クロルアセトアミドを加えて、5℃以
下で溶解した。これに10gの上記で調製した原糸1を
浸し、室温で2時間静置した。その後、繊維を取りだ
し、大過剰の冷メタノール中に入れ、洗浄した。繊維を
メタノールで良く洗った後、水洗し、乾燥して、15.
0gのα−クロルアセトアミドメチル化ポリスチレン繊
維(中間体1)を得た。中間体1は比較例1としても用
いた。また、10gの原糸2および10gの原糸3を同
様に処理して、中間体2(収量14.4g)および中間
体3(収量12.5g)を得た。(Intermediate) 3 g of paraformaldehyde was dissolved in a mixed solution of 600 mL of nitrobenzene and 390 mL of sulfuric acid at 20 ° C., then cooled to 0 ° C., and 75.9 g of N-
Methylol-α-chloroacetamide was added and dissolved at 5 ° C or lower. 10 g of the yarn 1 prepared above was dipped in this, and allowed to stand at room temperature for 2 hours. Then, the fiber was taken out, put into a large excess of cold methanol, and washed. After thoroughly washing the fibers with methanol, washing with water and drying, 15.
0 g of α-chloroacetamide methylated polystyrene fiber (intermediate 1) was obtained. Intermediate 1 was also used as Comparative Example 1. Further, 10 g of the raw yarn 2 and 10 g of the raw yarn 3 were treated in the same manner to obtain Intermediate 2 (yield 14.4 g) and Intermediate 3 (yield 12.5 g).
【0023】(親水性アミンの不均一系反応による固
定)N,N−ジメチルヘキシルアミン50gとヨウ化カ
リウム8gを360mLのDMFに溶かした溶液に5g
の中間体1を浸し、85℃のバス中で3時間加熱した。
繊維を1モル/L濃度の食塩水に浸漬した後、水洗し、
真空乾燥して、7.3gのジメチルヘキシルアンモニウ
ム化繊維(実施例1)を得た。(Immobilization of Hydrophilic Amine by Heterogeneous Reaction) 5 g of a solution prepared by dissolving 50 g of N, N-dimethylhexylamine and 8 g of potassium iodide in 360 mL of DMF.
Intermediate 1 was immersed and heated in a bath at 85 ° C. for 3 hours.
After immersing the fiber in 1 mol / L salt solution, washing it with water,
It was vacuum dried to obtain 7.3 g of dimethylhexylammonium fiber (Example 1).
【0024】また、N,N−ジメチルオクチルアミン5
0gとヨウ化カリウム8gを360mLのDMFに溶か
した溶液に5gの中間体1を浸し、85℃のバス中で3
時間加熱した。繊維をイソプロパノールで洗浄後、1モ
ル/L濃度の食塩水に浸漬した後、水洗し、真空乾燥し
て、8.3gのジメチルオクチルアンモニウム化繊維
(実施例2)を得た。Further, N, N-dimethyloctylamine 5
Immerse 5 g of Intermediate 1 in a solution of 0 g and 8 g of potassium iodide in 360 mL of DMF.
Heated for hours. The fiber was washed with isopropanol, immersed in a 1 mol / L concentration saline solution, washed with water, and vacuum dried to obtain 8.3 g of a dimethyloctylammonium-modified fiber (Example 2).
【0025】また、N,N−ジメチルラウリルアミン5
0gとヨウ化カリウム8gを360mLのDMFに溶か
した溶液に5gの中間体1を浸し、85℃のバス中で3
時間加熱した。繊維をイソプロパノールで洗浄後、1モ
ル/L濃度の食塩水に浸漬した後、水洗し、真空乾燥し
て、9.3gのジメチルラウリルアンモニウム化繊維
(実施例3)を得た。また、中間体2および中間体3を
同様に処理して、それぞれ実施例4(比表面積1.4m
2/g)および比較例4(比表面積0.04m2/g)を
得た。Further, N, N-dimethyllaurylamine 5
Immerse 5 g of Intermediate 1 in a solution of 0 g and 8 g of potassium iodide in 360 mL of DMF.
Heated for hours. The fiber was washed with isopropanol, immersed in a salt solution of 1 mol / L concentration, washed with water, and vacuum dried to obtain 9.3 g of dimethyllauryl ammonium modified fiber (Example 3). Moreover, the intermediate body 2 and the intermediate body 3 were treated in the same manner to obtain Example 4 (specific surface area 1.4 m).
2 / g) and Comparative Example 4 (specific surface area 0.04 m 2 / g) were obtained.
【0026】(非親水性アミンの不均一系反応による固
定)また、非親水性アミンとして、ステアリルアミン5
0gを360mLのエタノールに溶かした溶液に5gの
中間体1を浸し、85℃のバス中で3時間加熱した。繊
維をイソプロパノールで洗浄後、水洗し、真空乾燥し
て、7.2gのステアリルアミノ化繊維(比較例2)を
得た。(Immobilization of non-hydrophilic amine by heterogeneous reaction) Further, as non-hydrophilic amine, stearylamine 5
5 g of Intermediate 1 was immersed in a solution of 0 g in 360 mL of ethanol and heated in a bath at 85 ° C. for 3 hours. The fiber was washed with isopropanol, washed with water and vacuum dried to obtain 7.2 g of stearyl aminated fiber (Comparative Example 2).
【0027】(スルホン化繊維)また、パラホルムアル
デヒド500mgを溶解した硫酸50mLに、5gの原
糸1を浸し、95℃で1時間加熱した後、水洗、1モル
/L濃度の食塩水での洗浄、水洗、乾燥を逐次行って、
7.3gのスルホン化繊維(比較例3)を得た。(Sulfonated fiber) Further, 5 g of the raw yarn 1 was immersed in 50 mL of sulfuric acid in which 500 mg of paraformaldehyde was dissolved, heated at 95 ° C. for 1 hour, and then washed with water and washed with a 1 mol / L concentration saline solution. , Wash with water and dry sequentially,
7.3 g of sulfonated fiber (Comparative Example 3) was obtained.
【0028】(親水性アミン結合ポリマーの合成とコー
ティング)ニトロベンゼン16mLと硫酸32mLの混
合溶液を0℃に冷却後、4.2gのN−メチロール−α
−クロルアセトアミドを加えて、溶解し、これを、10
℃のユーデルポリスルホンP3500の3Lのニトロベ
ンゼン溶液(300g/3L)に、良く撹拌しながら加
えた。さらに、室温で3時間撹拌した。その後、反応混
合物を大過剰の冷メタノール中に入れ、ポリマーを沈殿
させた。沈殿をメタノールで良く洗った後、乾燥し、さ
らに、ジメチルホルムアミド/メタノールから再沈殿し
て、303gのα−クロルアセトアミドメチル化ポリス
ルホン(置換率:0.05;重合体C)を得た。(Synthesis and coating of hydrophilic amine-bonded polymer) After cooling a mixed solution of 16 mL of nitrobenzene and 32 mL of sulfuric acid to 0 ° C., 4.2 g of N-methylol-α
-Chloroacetamide was added and dissolved and this was mixed with 10
It was added to a 3 L nitrobenzene solution (300 g / 3 L) of Udel Polysulfone P3500 at 0 ° C. with good stirring. Furthermore, it stirred at room temperature for 3 hours. Then, the reaction mixture was put into a large excess of cold methanol to precipitate the polymer. The precipitate was thoroughly washed with methanol, dried, and then reprecipitated from dimethylformamide / methanol to obtain 303 g of α-chloroacetamidomethylated polysulfone (substitution rate: 0.05; polymer C).
【0029】ポリエチレンイミン(平均分子量1000
0:和光純薬)60gを300mLのDMFに溶かした
溶液と30gの重合体Cを含む300mLのDMF溶液
と混合し、室温で48時間撹拌した。反応混合物を大過
剰の飽和食塩水に加え、沈殿したポリマーをろ取した。
ポリマーを水洗後、乾燥し、さらに、ジメチルホルムア
ミド/メタノールから再沈殿して、27gのN−アルキ
ル化ポリアルキレンイミン固定化ポリスルホン(重合体
D)を調製した。Polyethyleneimine (average molecular weight 1000
(0: Wako Pure Chemical Industries, Ltd.) 60 g of a solution prepared by dissolving it in 300 mL of DMF was mixed with a 300 mL DMF solution containing 30 g of Polymer C, and the mixture was stirred at room temperature for 48 hours. The reaction mixture was added to a large excess of saturated saline, and the precipitated polymer was collected by filtration.
The polymer was washed with water, dried, and then reprecipitated from dimethylformamide / methanol to prepare 27 g of N-alkylated polyalkyleneimine-immobilized polysulfone (Polymer D).
【0030】上記重合体Dを5g含む塩化メチレン25
0mLの溶液に、単糸の直径が3.5μmのポリエチレ
ンテレフタレート繊維の綿20gを浸し、20時間後に
綿を取り出し、液を切って風乾し、21gのコーティン
グ綿(実施例5)を得た。Methylene chloride 25 containing 5 g of the above polymer D
20 g of polyethylene terephthalate fiber having a diameter of 3.5 μm of a single yarn was dipped in 0 mL of the solution, and after 20 hours, the cotton was taken out, drained and air dried to obtain 21 g of coated cotton (Example 5).
【0031】(非イオン性官能基の吸着材)酢酸セルロ
ース5gを塩化メチレン250mlに溶かし、単糸の直
径が3.5μmのポリエチレンテレフタレート繊維の綿
20gを浸し、20時間後に綿を取り出し、液を切って
風乾し、21gのコーティング綿(比較例5)を得た。(Nonionic functional group adsorbent) 5 g of cellulose acetate was dissolved in 250 ml of methylene chloride, 20 g of polyethylene terephthalate fiber having a single yarn diameter of 3.5 μm was soaked, and after 20 hours, the cotton was taken out and the liquid was removed. It was cut and air-dried to obtain 21 g of coated cotton (Comparative Example 5).
【0032】(吸着能の評価)8週令のHOS:Don
ryuラット(雄)の背部皮下にYS細胞(東北大学加
齢研究所提供)2×108個接種して調製した担癌ラッ
ト5匹から血液を採取し、血清30mLを調製した。そ
の血清1mLに吸着材50mgを入れ、37℃で4時間
振とうした。上清中の各蛋白質濃度を測定して、表1の
結果を得た。(Evaluation of Adsorption Ability) HOS: Don for 8 weeks
Blood was collected from 5 tumor-bearing rats prepared by inoculating 2 × 10 8 YS cells (provided by Tohoku University Aging Research Institute) subcutaneously on the back of ryu rat (male) to prepare 30 mL of serum. 50 mg of an adsorbent was added to 1 mL of the serum and shaken at 37 ° C. for 4 hours. The concentration of each protein in the supernatant was measured, and the results shown in Table 1 were obtained.
【0033】[0033]
【表1】 [Table 1]
【0034】表1の比較例1では比表面積が大きいにも
拘わらず、親水性アミノ基のリガンドがないため吸着性
がない。比較例2は親水性でないアミノ基のリガンドの
ため吸着能が無い。比較例3からスルホン酸基のリガン
ドは吸着性がないことが分かる。また、比較例4は親水
性アミノ基のリガンドであるが、実施例3及び実施例4
と異なり比表面積が低いため吸着能が殆ど無い。比較例
5及び比較例6は比表面積は小さくないが、親水性アミ
ノ基のリガンドがないため吸着能がない。これらの結果
から、吸着には親水性アミンの官能基が必要であるこ
と、比表面積が0.04平方メートルでは吸着能が低い
ことが分かる。また、親水性アミンの中でも、窒素原子
1個当たりの炭素数が14のものより10および8のも
のの吸着能が大きいことが分かる。In Comparative Example 1 of Table 1, despite having a large specific surface area, there is no adsorptive property because there is no hydrophilic amino group ligand. Comparative Example 2 has no adsorptive ability because it is a non-hydrophilic amino group ligand. From Comparative Example 3, it can be seen that the ligand having a sulfonic acid group has no adsorptivity. In addition, Comparative Example 4 is a hydrophilic amino group ligand, but Examples 3 and 4
Unlike that, it has almost no adsorption capacity because of its low specific surface area. Comparative Examples 5 and 6 are not small in specific surface area, but have no adsorptive ability because there is no hydrophilic amino group ligand. From these results, it is understood that the adsorption requires a functional group of hydrophilic amine, and that the adsorption capacity is low when the specific surface area is 0.04 square meters. Further, among the hydrophilic amines, it can be seen that the adsorption ability of 10 and 8 having a carbon number per one nitrogen atom is larger than that having 14 carbon atoms.
【0035】[0035]
【発明の効果】本発明により、免疫抑制性物質を効率よ
く吸着除去することが可能となり、癌の患者の治療に有
用である。INDUSTRIAL APPLICABILITY According to the present invention, an immunosuppressive substance can be efficiently adsorbed and removed, which is useful for the treatment of cancer patients.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) B01J 20/28 B01J 20/28 A Z (72)発明者 渡辺 幸二 滋賀県大津市園山1丁目1番1号 東レ株 式会社滋賀事業場内 Fターム(参考) 4C077 AA12 BB03 CC06 EE01 HH03 JJ03 KK11 LL02 MM03 NN04 PP08 PP12 PP14 PP15 4G066 AC14C AC31C AD06B AD10B BA03 BA09 CA20 DA12 EA01 FA11 FA25 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) B01J 20/28 B01J 20/28 AZ (72) Inventor Koji Watanabe 1-1-1, Sonoyama, Otsu City, Shiga Prefecture No. Toray Co., Ltd. Shiga Plant F term (reference) 4C077 AA12 BB03 CC06 EE01 HH03 JJ03 KK11 LL02 MM03 NN04 PP08 PP12 PP14 PP15 4G066 AC14C AC31C AD06B AD10B BA03 BA09 CA20 DA12 EA01 FA11 FA25
Claims (10)
トル以上であり、水不溶性担体に親水性アミン残基を結
合してなる免疫抑制性蛋白質吸着材。1. An immunosuppressive protein adsorbent having a specific surface area of 0.1 square meter or more per gram and comprising a hydrophilic amine residue bound to a water-insoluble carrier.
素数3以上18以下である第4級アンモニウム基である
請求項1記載の免疫抑制性蛋白質吸着材。2. The immunosuppressive protein adsorbent according to claim 1, wherein the hydrophilic amine residue is a quaternary ammonium group having 3 to 18 carbon atoms per nitrogen atom.
・グロウス・ファクター・ベータである請求項1記載の
免疫抑制性蛋白質吸着材。3. The immunosuppressive protein adsorbent according to claim 1, wherein the immunosuppressive protein is transforming growth factor beta.
る請求項1記載の免疫抑制性蛋白質吸着材。4. The immunosuppressive protein adsorbent according to claim 1, wherein the immunosuppressive protein is an immunosuppressive acidic protein.
る請求項1記載の免疫抑制性蛋白質吸着材。5. The immunosuppressive protein adsorbent according to claim 1, wherein the water-insoluble carrier is a polysulfone polymer.
物)である請求項1記載の免疫抑制性蛋白質吸着材。6. The immunosuppressive protein adsorbent according to claim 1, wherein the water-insoluble polymer is poly (aromatic vinyl compound).
体を膜、繊維、粒状物またはこれらの組み立て品に成型
した請求項1記載の免疫抑制性蛋白質吸着材。7. The immunosuppressive protein adsorbent according to claim 1, wherein the water-insoluble polymer having a hydrophilic amine residue bonded thereto is molded into a film, a fiber, a granular material or an assembly thereof.
を、膜、繊維、粒状物のいずれかの表面に被覆せしめた
請求項1記載の吸着材。8. The adsorbent according to claim 1, wherein the surface of any one of a membrane, a fiber and a granular material is coated with a water-insoluble polymer having a hydrophilic amino group bonded thereto.
カラム。9. An extracorporeal circulation column packed with the adsorbent according to claim 1.
用体外循環カラム。10. An extracorporeal circulation column for cancer treatment, which is packed with the adsorbent according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001307333A JP4009772B2 (en) | 2001-10-03 | 2001-10-03 | Adsorbent and extracorporeal circulation column for transforming growth factor beta |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001307333A JP4009772B2 (en) | 2001-10-03 | 2001-10-03 | Adsorbent and extracorporeal circulation column for transforming growth factor beta |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2003111834A true JP2003111834A (en) | 2003-04-15 |
JP2003111834A5 JP2003111834A5 (en) | 2005-03-03 |
JP4009772B2 JP4009772B2 (en) | 2007-11-21 |
Family
ID=19126810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001307333A Expired - Lifetime JP4009772B2 (en) | 2001-10-03 | 2001-10-03 | Adsorbent and extracorporeal circulation column for transforming growth factor beta |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4009772B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006312804A (en) * | 2005-04-08 | 2006-11-16 | Toray Ind Inc | Adsorbent material and column for extracorporeal circulation |
JP2007202634A (en) * | 2006-01-31 | 2007-08-16 | Toray Ind Inc | Adsorption device |
JP2007222596A (en) * | 2006-01-30 | 2007-09-06 | Toray Ind Inc | Sucker for leukocyte and cytokine |
JP2007260216A (en) * | 2006-03-29 | 2007-10-11 | Toray Ind Inc | Adsorbent carrier and column for extracorporeal circulation |
WO2008038785A1 (en) * | 2006-09-29 | 2008-04-03 | Toray Industries, Inc. | Cell-adsorbing column |
JP2010201345A (en) * | 2009-03-03 | 2010-09-16 | Kazuo Teramoto | Porous adsorbent |
US8584869B2 (en) | 2005-03-31 | 2013-11-19 | Toray Industries, Inc. | Absorbent and column for extracorporeal circulation |
US9127250B2 (en) | 2011-03-29 | 2015-09-08 | Shiga University Of Medical Science | Immunosuppressive cell-capturing material and immunosuppressive cell-capturing column |
-
2001
- 2001-10-03 JP JP2001307333A patent/JP4009772B2/en not_active Expired - Lifetime
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8584869B2 (en) | 2005-03-31 | 2013-11-19 | Toray Industries, Inc. | Absorbent and column for extracorporeal circulation |
JP2006312804A (en) * | 2005-04-08 | 2006-11-16 | Toray Ind Inc | Adsorbent material and column for extracorporeal circulation |
JP2007222596A (en) * | 2006-01-30 | 2007-09-06 | Toray Ind Inc | Sucker for leukocyte and cytokine |
JP2007202634A (en) * | 2006-01-31 | 2007-08-16 | Toray Ind Inc | Adsorption device |
JP2007260216A (en) * | 2006-03-29 | 2007-10-11 | Toray Ind Inc | Adsorbent carrier and column for extracorporeal circulation |
WO2008038785A1 (en) * | 2006-09-29 | 2008-04-03 | Toray Industries, Inc. | Cell-adsorbing column |
JP5136418B2 (en) * | 2006-09-29 | 2013-02-06 | 東レ株式会社 | Cell adsorption column |
KR101398768B1 (en) * | 2006-09-29 | 2014-05-27 | 도레이 카부시키가이샤 | Cell-adsorbing column |
JP2010201345A (en) * | 2009-03-03 | 2010-09-16 | Kazuo Teramoto | Porous adsorbent |
US9127250B2 (en) | 2011-03-29 | 2015-09-08 | Shiga University Of Medical Science | Immunosuppressive cell-capturing material and immunosuppressive cell-capturing column |
Also Published As
Publication number | Publication date |
---|---|
JP4009772B2 (en) | 2007-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU660425B2 (en) | High efficiency removal of low density lipoprotein-cholesterol from whole blood | |
JPH09508823A (en) | Devices and processes for the removal of leukocytes and virus inactivating agents from blood. | |
CN101817519A (en) | Preparation method and use of millimetre-sized mesoporous carbon spheres | |
WO1999011304A1 (en) | Leukocyte-removing filter material | |
JP2003111834A (en) | Adsorbent for immunosuppressive protein and column for extracorporeal circulation | |
CN107638612A (en) | A kind of anti-coagulation anti-bacterial type remaining needle sleeve pipe and preparation method thereof | |
US8932590B2 (en) | Method of adsorbing transforming growth factor β | |
JP4182682B2 (en) | Carcinoembryonic antigen adsorbent and extracorporeal circulation column | |
JP2006288571A (en) | Adsorbent for cancer treatment and column for extracorporeal circulation | |
JP4032465B2 (en) | Thrombogenic substance adsorbent and extracorporeal circulation column | |
JP2777604B2 (en) | Adsorbent for body fluid treatment | |
JPS63236539A (en) | Immunoglobulin selective adsorbent | |
JP2004248950A (en) | Adsorbing material for immunosuppressive substance and column for extracorporeal circulation | |
JP4200689B2 (en) | Extracorporeal circulation column for cancer treatment | |
CA2961454A1 (en) | Fiber for protein adsorption and column for protein adsorption | |
JP2004073618A (en) | Adsorbent and extracorporeal circulation column filled with the adsorbent | |
JP4779190B2 (en) | Inflammatory disease treatment column | |
JP2007313288A (en) | Adsorbing carrier and column for extracorporeal circulation | |
JP4453395B2 (en) | Use of extracorporeal circulation column suitable for cancer treatment | |
JP2002113097A (en) | Adsorbent and in vitro circulation column | |
JP2004248951A (en) | Adsorbing material and column for extracorporeal circulation filled with it | |
CN113677429A (en) | Adsorption material of soluble tumor necrosis factor receptor | |
JP3157026B2 (en) | Adsorbent for blood purification | |
JP4228498B2 (en) | Heparin adsorbent and method for removing heparin using the same | |
CN109046282B (en) | Adsorbent for removing endotoxin by hemoperfusion and water solution and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040330 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040330 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060525 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060606 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060804 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070130 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070329 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070515 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070702 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070820 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4009772 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100914 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110914 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120914 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130914 Year of fee payment: 6 |